HTG Molecular Diagnostics, Inc. Common Stock
HTGM
HTGM was delisted on the 14th of June, 2023.
33 hedge funds and large institutions have $5.79M invested in HTG Molecular Diagnostics, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 1 closing their positions.
800% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 1
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
22% more funds holding
Funds holding: 27 → 33 (+6)
57% less capital invested
Capital invested by funds: $13.3M → $5.79M (-$7.53M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CPA
Cowen Prime Advisors
New York
|
+$1.26M |
| 2 |
Squarepoint
New York
|
+$51.8K |
| 3 |
First Manhattan
New York
|
+$34.8K |
| 4 |
BlackRock
New York
|
+$33.8K |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$32.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.05M |
| 2 |
HWM
HighMark Wealth Management
St. Paul,
Minnesota
|
-$82.7K |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$52.4K |
| 4 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$50.6K |
| 5 |
EGM
Engineers Gate Manager
New York
|
-$18K |
HTGM Hedge Fund Activity: Q1 2020 in Review
33 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics, Inc. Common Stock (HTGM) for Q1 2020, worth a combined $5.79M — down 57% from $13.3M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new HTGM positions and 1 closed out — a net gain of 8 holders — while 10 added to existing stakes and 6 trimmed.
The largest buyer was Cowen Prime Advisors, adding an estimated $1.26M. The largest seller was Stonepine Capital Management, cutting an estimated $2.05M.
- 33 institutional investors held HTG Molecular Diagnostics, Inc. Common Stock (HTGM) as of Q1 2020, up from 27 in Q4 2019.
- Funds reported $5.79M of HTG Molecular Diagnostics, Inc. Common Stock stock for Q1 2020, down 57% quarter-over-quarter.
- 9 funds opened new HTG Molecular Diagnostics, Inc. Common Stock positions in Q1 2020 and 1 closed out, a net change of +8 holders.
- The largest HTG Molecular Diagnostics, Inc. Common Stock buyer in Q1 2020 was Cowen Prime Advisors, an estimated $1.26M added.
- The largest HTG Molecular Diagnostics, Inc. Common Stock seller in Q1 2020 was Stonepine Capital Management, an estimated $2.05M sold.
Based on aggregated 13F filings for Q1 2020.